Catching Up with the Latest Scientific Publications on Myasthenia Gravis

In the last few months, some scientific articles have really caught my attention. I’m not saying they are the most important publications done lately, just the ones that I have found relevant as a patient.

The “Nordic Article”

The so-called “Nordic article” A guide that is focused only on treatments for generalized MG with acetylcholine receptor antibodies (AChR-MG). I found it marvelous also because some of the coauthors are MG patients. I’m really very grateful that our voices are heard and included.

Pregnancy in Myasthenia Gravis

A publication about pregnancy in MG. A recent retrospective analysis explored maternal and neonatal outcomes in pregnant women with MG. While the study provides reassurance, it’s essential to remember that pregnancy with MG requires careful monitoring. Seek care from a specialized medical team experienced in managing MG during pregnancy. A good hospital with excellent neonatal care is crucial for a safe and healthy pregnancy journey.

ClC-1 Chloride Channel Inhibitor: A Potential Breakthrough

And last but not least: For the first time in many years, a new symptomatic treatment for myasthenia gravis seems to be effective.

A recent study investigated the ClC-1 chloride channel inhibitor. While more research is needed, exploring this possibility hold promise.

Why I found these articles interesting as a patient:

It is important to have a new symptomatic treatment.

Almost worldwide, we use mostly only pyridostigmine, even though in very few countries Ambenonium Chloride is also available. Neostigmine is also not used in all countries, and in some is mostly used in a hospital setting.

Therefore, most of the time, we rely on pyridostigmine, which not only is often in short supply in various parts of the world but also doesn’t work for everyone. The most common formulation contains lactose. The alternative without lactose is not available everywhere. In many countries, formulations with different dosages are not present. These are all fewer alternatives that make everything very precarious.

For this reason, just knowing about the possibility of having an alternative with a different mechanism of action in the future is good news for all of us. An additional option, especially for those who cannot use the few available treatments we have now.

The Nordic article is a very clear guide, and it's nice to know that patients were involved in writing the article.

The article on pregnancy and MG is also welcome because we hope that more research will be done in this direction.

Disclaimer: This article is not sponsored and does not intend to provide any medical advice. Staying informed as patients is important; if you have any doubts, consult your doctor.